Effects of immune checkpoint inhibitor therapy resumption in patients with malignant tumors after moderate-to-severe immune-related adverse events.

Por Machiko Kawahira, Shuji Kanmura, Keiko Mizuno, Kentaro Machida, Takao Ohtsuka, Masami Sato, Hideki Enokida, Masaru Yamashita, Takuro Kanekura, Shiho Arima, Norifumi Nakamura, Tsuyoshi Sugiura, Koji Yoshimoto, Hiroaki Kobayashi, Kenji Ishitsuka, Shinsuke Suzuki, Shinichi Ueno, Akio Ido
Publicado em 2022-01-01